Skip to content

Palvella Therapeutics PVLA Net Investment in Lease

Net Investment in Lease at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Precigen logo
PrecigenPGEN
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's net investment in lease?
Palvella Therapeutics (PVLA) reported net investment in lease of $528K in Q1 2026.
What is the long-term trend for Palvella Therapeutics's net investment in lease?
Over 4 years (2020 to 2025), Palvella Therapeutics's net investment in lease has grown at a -38.2% compound annual growth rate (CAGR), from $3.93M to $572K.